The takeaway
Solid Biosciences LLC shows a pronounced seasonal pattern over 8 years of data — strongest in December (+22.0%) and softest in October (−11.0%).
Right now
In July, the stock has risen 63% of years, averaging +9.4%, about +7.2 pts better than the S&P 500.
The full picture
Solid Biosciences LLC's most dependable month has been December, higher in 5 of 8 years; October has been its least reliable, up just 13% of the time.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Win rate % | ||||||||||||
| Median return % | ||||||||||||
| 2025 | ||||||||||||
| 2024 | ||||||||||||
| 2023 | ||||||||||||
| 2022 | ||||||||||||
| 2021 | ||||||||||||
| 2020 | ||||||||||||
| 2019 | ||||||||||||
| 2018 |
Month by month
The stock's clearest edge over the S&P 500 lands in December (+21.0 pts); it has trailed the market most in March (−14.7 pts).
“vs S&P” is Solid Biosciences LLC’s average for a month minus the S&P 500’s average for that same month — isolating Solid Biosciences LLC’s own seasonal edge from broad market drift.
Reality check
Over the last 5 years, December has closed higher 60% of the time versus 63% across the last 8 years — the pattern is holding.
Figures are the typical (median) December return and how often it rose — the last 5 years versus the last 8(the heatmap’s default window). This verdict stays anchored to that 8-year window even if you zoom the chart, so it never disagrees with the badges above.
In plain English
December looks the standout, up in 5 of 8 Decembers — yet the appeal is lumpy, leaning on the occasional blow-out year rather than dependable strength.
The headline flatters a touch — its +22.0% average sits well above the +3.0% a typical year delivers, the work of a few big Decembers. That reliability comes with real swings, mind — even December ranges by 53.4% from year to year, so any single year can land far from the average. Crucially, the gain is the stock's own rather than a rising tide's: December has cleared the S&P 500 by +21.0 points above the index.
Only July comes anywhere near it for reliability. On the other side of the ledger, October has been the soft spot — the weakest of 5 months that average a loss (−11.0%), and the edge isn't year-round — the stock has trailed the S&P 500 in March, October, and November. Its roughest month on record was a −75.3% March in 2018 — a reminder of how hard even a seasonal name can fall.
Reassuringly, the tendency has held its shape: the recent five years still track the years behind them.
Hold it loosely, then: the December tendency is genuine but lumpy, more about the occasional outsized year than a gain to bank on. With a short 8-year record and returns that swing hard year to year, the signal is best held loosely.
Short answers on the stock's best month (December), its worst (October), and whether it really trades seasonally.
Yes, to a pronounced degree. Since 2018 its best month (December, +22.0%) has run well ahead of its worst (October, −11.0%) — the heatmap above shows how steady that gap has been year to year.
December has been the strongest, averaging +22.0% and closing higher in 5 of 8 years since 2018.
It's the weakest, averaging −11.0% — historically a soft spot, though it still varies from year to year.
Explore
These names have the strongest July track records on record — a starting point for comparison.
Before you trade